Notably, patients with tumours with high BCL-2 expression had a significantly worse OS (9.1 versus 12.8 months) (HR 1.63, 95% CI 1.02–2.61, p = 0.038), though high BCL-2 was seen in only a small percentage of samples. This evidence concerns the gene BCL2 and neoplasm.